Holen Sie sich die Stockscreener-App
27.28
5.11%
-1.47
Handel nachbörslich:
27.41
0.13
+0.48%
Harrow Inc Aktie (HROW) Neueste Nachrichten
Harrow stock seeks rebound - Nashville Post
Do Options Traders Know Something About Harrow Stock We Don't? - Zacks Investment Research
Viatris Inc. (VTRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
TYRVAYA is the only FDA-approved nasal spray for dry eye. Harrow acquired its rights outside Japan. - Stock Titan
Ocular Therapeutix, Inc.Common Stock (NQ: OCUL - The Chronicle-Journal
Is Harrow Inc (HROW) a Bargain After 5.7% Drop? GF Value Says Un - GuruFocus
Harrow at Cantor healthcare conference: long view, bigger eye-care bet - investing.com
HROW Initiates Coverage On Harrow -- Outperform Rating by Leerin - GuruFocus
Harrow (NasdaqGM:HROW) Stock Forecast & Analyst Predictions - Simply Wall Street
Andrew R. Boll Assumes Principal Accounting Officer Role at Harrow (NASDAQ: HROW) - Kalkine Media
Harrow Inc. (HROW) Slides 2.96% to $37.4, Approaches Support at $35.53Risk Reward Setups - dars.gov.et
Harrow Inc. (HROW) Slides 2.96% to $37.4, Approaches Support at $35.53Tick Index - dars.gov.et
Andrew R. Boll named Harrow principal accounting officer as Randall E. Pollard departs - TradingView
Harrow, Inc. Announces Management Changes, Effective September 4, 2026 - marketscreener.com
Harrow Health Inc. (HROW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
HROW Q2 2026 Earnings: EPS Misses Estimates as Losses DeepenMid-Term Outlook - vinanet.vn
Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
HROW Q2 2026 Earnings: EPS Misses Estimates as Losses DeepenEarnings Risk Report - dars.gov.et
Harrow Inc stock gains as analysts see strong revenue growth ahead - ad-hoc-news.de
Harrow Inc (HROW) Stock Up 5.6% and Still Undervalued -- GF Scor - GuruFocus
Harrow to Participate in Three Investor Conferences in September - GlobeNewswire
Harrow (HROW) Reported Positive IHEEZO Study Results In Intravitreal Injections - Sahm
Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move - vinanet.vn
Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move: Shares Move Lower 2.81% at the CloseEarnings Recovery Stocks - dars.gov.et
HROW | Harrow, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half - Sahm
Harrow (NASDAQ: HROW) CSO sells 11,250 shares in August option trade - Stock Titan
Harrow (HROW) Outlook: Ends Down by 2.64% at $40.95 for the Current Session; Next Session: Price Remains Between $38.90 Support and $43.00 Resistance on the DayShort Term Trading Ideas - vinanet.vn
What's Going On With Harrow Stock Friday?Harrow (NASDAQ:HROW) - Benzinga
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections - Sahm
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target - Yahoo Finance
In a 50-patient study, Harrow’s eye gel was linked to about 58% less injection discomfort - Stock Titan
Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In? - simplywall.st
Harrow And 2 Other Growth Stocks Insiders Are Betting On - simplywall.st
Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com South Africa
Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com
Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com Canada
Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com India
Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com
Rice Hall James & Associates LLC Takes Position in Harrow, Inc. $HROW - MarketBeat
Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy? - simplywall.st
Harrow (HROW) Q2 2026 Earnings Call Transcript - The Globe and Mail
Harrow (NASDAQ:HROW) Insider Amir Shojaei Sells 11,250 Shares - MarketBeat
Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneLast Point Resistance - vinanet.vn
Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneSweep Order Flow - dars.gov.et
HROW Q2 2026 Earnings: Wider Loss of $0.34 per Share Misses Estimates by 85.19%, but Stock Rises 2.98 - vinanet.vn
Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold" - MarketBeat
HC Wainwright Issues Pessimistic Outlook for Harrow Earnings - marketbeat.com
Royce Micro-Cap Fund's Harrow Inc(HROW) Holding History - GuruFocus
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
2.08%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):